HHSE - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture.

The SONY relationship includes the opportunity to place Hannover House represented titles into their network of direct distribution divisions in all major territories worldwide.

Status HHSE Audits, Form 10, Uplist To OTCQB

Hannover House taps new advisors in anticipation of Stock Registration

Jan 05, 2018

Fayetteville, AR -

Hannover House, Inc. (OTC: HHSE) has engaged two professional service advisors to assist in general operational needs and other activities and reporting requirements relating to the company's upcoming filing of a Form 10 Registration Statement with the Securities and Exchange Commission.

CPA Lisa Lashley Higgins has been engaged to review the company's books, records and financial filings covering the years 2015, 2016 and 2017, and to verify compliance with the needs set forth by the company's auditors. Attorney Steven H. Kay has been engaged to provide general transactional legal counsel, as well as filings relating to the elimination of contestable debts and prior litigation matters.

Hannover House, Inc. shares are currently traded on the OTC Pinksheets market. Upon acceptance of the company's registration statement by the Securities and Exchange Commission, the company anticipates that its shares will be elevated for exchange under the OTC: QB moniker. Contemporaneously with the registration filing, Hannover House will take steps to have its shares cleared under DTC electonic means, which management feels is a further step towards improving access and liquidity to the company's shares.

Hannover House was formed in 1993 as a book publishing house and has been operating continuously for the past 25-years. The company became publicly traded (as "Target Development Group, Inc.") in Dec. 2009, under a stock-for-stock swap structure with the principal Hannover House managers (Eric Parkinson and Fred Shefte) taking over managerial control. An investment agreement made in December 2009 with Bedrock Ventures was intended to provide the company with $1.5-mm in operating capital, but was only partially funded, resulting in two years of significant financial duress for Hannover House (2010 and 2011). The company has since retired over $5-million in debt and has refocused operations on higher-profile motion pictures, primarily those suitable for theatrical release. The company has not made any new stock-for-debt agreements in over 2-1/2 years, and has not issued any new shares since August, 2015, evidencing both the commitment to build shareholder value, as well as the internal capabilities to manage growth, operations and further debt reductions from cash flows, servicing fees and non-toxic funding structures.

Recent product releases for Hannover House include the Nov. theatrical title, "BATTLECREEK" from director Alison Eastwood, starring "IT" superstar Bill Skarsgard; and the Dec. theatrical title "DAISY WINTERS" starring Brooke Shields and Game of Thrones star Iwan Rheon. Upcoming releases include the horror titles "BLOODFEAST", "DEATH HOUSE", "MUSE" and INSOMNIUM", and the faith-based features "SACRED HEARTS" and "GETTING GRACE." The company also just completed principal photography on the western-thriller, "THE RIOT ACT," and is in pre-production / development for "DELIRIUM", "LAST CHANCE FOR HONOR" and "MOTHER GOOSE: JOURNEY TO UTOPIA" - the later three of which are expected to benefit from State of Arkansas production incentives, tax benefits and rebates. "BATTLECREEK" will hit video shelves as a DVD and BluRay release on February 6, with placement into Walmart, Target, Best Buy, Family Video and many other indie retailers. From the book publishing side, a new tradeback edition of "QUIETUS" from author Vivian Schilling, will hit retail shelves on February 27, including Barnes & Noble and Books-A-Million locations (prior editions of "Quietus" have collectively sold over 100,000 copies).

* * * * *
http://www.otcmarkets.com/stock/HHSE/news/Hannover-House-taps-new-advisors-in-anticipation-of-Stock-Registration?id=179687&b=y

HHSE: Hannover House taps new advisors in anticipation of Stock Registration

Jan 05, 2018

Fayetteville, AR -

Hannover House, Inc. (OTC: HHSE) has engaged two professional service advisors to assist in general operational needs and other activities and reporting requirements relating to the company's upcoming filing of a Form 10 Registration Statement with the Securities and Exchange Commission.

CPA Lisa Lashley Higgins has been engaged to review the company's books, records and financial filings covering the years 2015, 2016 and 2017, and to verify compliance with the needs set forth by the company's auditors. Attorney Steven H. Kay has been engaged to provide general transactional legal counsel, as well as filings relating to the elimination of contestable debts and prior litigation matters.

Hannover House, Inc. shares are currently traded on the OTC Pinksheets market. Upon acceptance of the company's registration statement by the Securities and Exchange Commission, the company anticipates that its shares will be elevated for exchange under the OTC: QB moniker. Contemporaneously with the registration filing, Hannover House will take steps to have its shares cleared under DTC electonic means, which management feels is a further step towards improving access and liquidity to the company's shares.

Hannover House was formed in 1993 as a book publishing house and has been operating continuously for the past 25-years. The company became publicly traded (as "Target Development Group, Inc.") in Dec. 2009, under a stock-for-stock swap structure with the principal Hannover House managers (Eric Parkinson and Fred Shefte) taking over managerial control. An investment agreement made in December 2009 with Bedrock Ventures was intended to provide the company with $1.5-mm in operating capital, but was only partially funded, resulting in two years of significant financial duress for Hannover House (2010 and 2011). The company has since retired over $5-million in debt and has refocused operations on higher-profile motion pictures, primarily those suitable for theatrical release. The company has not made any new stock-for-debt agreements in over 2-1/2 years, and has not issued any new shares since August, 2015, evidencing both the commitment to build shareholder value, as well as the internal capabilities to manage growth, operations and further debt reductions from cash flows, servicing fees and non-toxic funding structures.

Recent product releases for Hannover House include the Nov. theatrical title, "BATTLECREEK" from director Alison Eastwood, starring "IT" superstar Bill Skarsgard; and the Dec. theatrical title "DAISY WINTERS" starring Brooke Shields and Game of Thrones star Iwan Rheon. Upcoming releases include the horror titles "BLOODFEAST", "DEATH HOUSE", "MUSE" and INSOMNIUM", and the faith-based features "SACRED HEARTS" and "GETTING GRACE." The company also just completed principal photography on the western-thriller, "THE RIOT ACT," and is in pre-production / development for "DELIRIUM", "LAST CHANCE FOR HONOR" and "MOTHER GOOSE: JOURNEY TO UTOPIA" - the later three of which are expected to benefit from State of Arkansas production incentives, tax benefits and rebates. "BATTLECREEK" will hit video shelves as a DVD and BluRay release on February 6, with placement into Walmart, Target, Best Buy, Family Video and many other indie retailers. From the book publishing side, a new tradeback edition of "QUIETUS" from author Vivian Schilling, will hit retail shelves on February 27, including Barnes & Noble and Books-A-Million locations (prior editions of "Quietus" have collectively sold over 100,000 copies).

* * * * *
http://www.otcmarkets.com/stock/HHSE/news/Hannover-House-taps-new-advisors-in-anticipation-of-Stock-Registration?id=179687&b=y

HHSE-Where we have been... Where we are now... and Where we are going at HHSE...

WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?

* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.

* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.

What else is worth noting for this long, holiday weekend? Here are a few observations:

1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.

3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.

The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.

A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.

There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

HHSE Board of Directors approves Uplisting / Registration Costs

Dear HHSE Friends, Followers & Shareholders: At a special meeting of the Board of Directors of Hannover House, Inc., held on Thursday, October 19 at 11:00-am, the Board voted unanimously to immediately reinstate the prior filing activities to register the company's stock shares with the Securities and Exchange Commission (Form 10). The Board also authorized the following budgetary expenditures - to be funded from ongoing cash flows - to promptly complete this task:

HHSE

Steps and Budget for UPLISTING




Item
Description
Amount
1
Internal Data Entry
$ 4,000
2
Completion of New Library Valuation
$ 20,000
3
Outside CPA Review
$ 4,500
4
PCAOB Audit
$ 50,000
5
Legal Review & Drafting
$ 6,500
6
Registration S.E.C. Filings & XBRL
$ 3,250




FIRST TIME - UPLIST REGISTRATION COSTS
$ 88,250




Ongoing Quarterly Auditor's Review
$ 5,000

Ongoing Quarterly Attorney's Review
$ 2,000

Annual Review of Q4 & prior 3-Q's
$ 20,000

Annual Attorney review and drafting
$ 3,000




ANNUAL MAINTENANCE TOTALS
$ 44,000



The one-time costs for the registration / uplist are estimated at $88,250. The ongoing (annualized) maintenance costs are estimated at $44,000 (inclusive of the Quarterly Reviews by the PCAOB Auditing firm, and the annual year-end report and legal review).

Based on current cash flow and resources - and considering the anticipated benefits to the Company and its shareholders for HHSE as a fully registered equity - the Board has authorized the immediate implementation of this plan and the authorization of these expenditures.

The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows.
****
PRODUCT$-PRODUCT$-PRODUCT$. GETTING.GRACE-WHERE'S.THE.DRAGON-BLOODFEAST-DAISY.WINTERS-BATTLECREEK & OTHERS

GETTING GRACE - Hot on the heels of a major NYC Market festival SWEEP of all major awards, HHSE will be releasing this Faith-Based Comedy-Drama nationwide on February 10, 2018 - with an outreach campaign that includes mega-churches and a key-market BUS TOUR with star and director DANIEL ROEBUCK ("Matlock", "The Fugitive") to drive local market enthusiasm.

WHERE'S THE DRAGON - With the dissolution of the merger between HHSE and Crimson Forest, the company is finally cleared to revert back to the terms of the Dec. 2016 distribution agreement for this title. Accordingly, on February 3, 2018, this enchanting Animated Feature will be released to theatres in key markets, in advance of a May, 2018 Home Video and V.O.D. launch.

DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant) number of theatres!

CHOSEN - this impressive World War II thriller continues to get theatrical bookings in key USA markets, and now into CANADA (Toronto, Ottawa, Calgary and Vancouver)... watch for playdates in December and January.

BLOODFEAST - Now that the MPAA has approved our fourth edit for "R-Rating Status" - we can FINALLY get mainstream theatres to book this picture... watch for a roll-out beginning Nov. 17 into top markets (staggered over a 2-month period).


DAISY WINTERS - a much broader release (over 100 theatres) is set for December 1st for this awards-worthy drama featuring stunning performances from Brooke Shields and a breakout performance from young Sterling Jerins in the title role. The Media support has already begun, fueled by the Hannover House MEDIA DAY in NYC on Sept. 26, plus a special event premiere at the Regal Union Square (NYC) on Oct. 5. Already, Brooke has appeared on several national talk shows promoting DAISY WINTERS, including Bravo's WATCH WHAT HAPPENS LIVE and the highly rated TODAY SHOW on NBC. Much more to come, including major feature stories in People Magazine, USA Today, Closer, In-Touch, ACCESS HOLLYWOOD, EXTRA and E! TV.

BATTLECREEK - the acclaimed dramatic thriller from director ALISON EASTWOOD opens in two weeks (Nov. 3), in approx. 20 locations in key USA Markets. The film's primary star is BILL SKARSGARD, well-known from his current smash hit "IT" (he plays Pennywise, the scary clown), and his upcoming Stephen King TV series, "Castlerock." We have been fortunate to receive major media support for BATTLECREEK, including National TV show placements on: ACCESS HOLLYWOOD, EXTRA, E! and ENTERTAINMENT TONIGHT, and Alison Eastwood interview appearances on FOX AND FRIENDS, THE VIEW, TALK, GOOD DAY NY and HOME AND FAMILY. There will be an "Eastwood Family Screening Event" in Los Angeles on opening night (Nov. 3), which will be open to the public (and is expected to generate good attendance).

****
BOGUS DEFAULT JUDGMENTS EVAPORATED: PHOTOG($2.2M),TCA($400K),REDBULL($250K),AMITYVILLE($300K).

THESE BOGUS DEFAULTS WERE SUPPOSED TO BK THE COMPANY. LMAO.
****
VODWIZ UPDATE - As anticipated, we have closed a major studio venture that will provide tonnage of product to VODWIZ, including a large quantity of recent, theatrical hits. The totality of programming that will be available to consumers through VODWIZ appears to be on track to being second only to Amazon at this point. We see VODWIZ as a major portal for home entertainment digital streaming access, and potentially "the tail that wags the dog" so to speak. Additionally, we are about a week away from the anticipated finalization of a private funding structure to finance the costs associated with building the VODWIZ website (to Amazon Digital infrastructure standards), and all other pre-launch and initial consumer launch costs for this venture.

MORE VODWIZ - there's another MAJOR STUDIO ALERT in the works! Over the past three years of development, two Major Studios (each offering a small "test quantity" of titles for VODWIZ), were secured to support the initial launch of this streaming operation. Now, we are poised for a very major development of a third Major Studio with over 500 high-profile, ready-to-place titles available for the VODWIZ streaming platform. HHSE key managers (Fred Shefte and Eric Parkinson) are meeting at the studio in southern California on Friday to discuss the logistics of this venture, which is already documented through a participation term sheet.
****
DAISY WINTERS WILL EASILY MAKE $2.5M+ FROM POST-THEATRICAL REVENUE SOURCES SUCH AS DVDS, BLUE RAYS, TV AND VOD (NETFLIX, VODWIZ, ETC). AS EVERYONE KNOWS, A THEATRICAL RELEASE SIMPLY SATISFIES REQUIREMENTS AND GREATLY AMPLIFIES LIFETIME REVENUES OF A TITLE.


"BATTLECREEK" PROVED THAT POST-THEATRICAL PROCEEDS ARE WHAT MATTER. THEATRICAL RELEASE OF SMALL INDIE MOVIES ARE JUST PRE-REQUISITES FOR MUCH LARGER PROFITS FROM DVD, BLUE RAY, VOD AND TV REVENUES. JUST LOOK AT THE RATIO OF BATTLECREEK PROCEEDS FROM BOX OFFICE VS. $1M+ PROCEEDS FROM POST-THEATRICAL REVENUES.

BUT EVERYONE ALREADY KNEW THIS, SINCE IT WAS CLEARLY EXPLAINED IN THE BLOGS AND PROVEN IN THE MARKETPLACE MANY TIMES.


http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html

How major? Well - based on video preorders already received from Walmart, Target, Best Buy, K-Mart and Family Video - BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.

***
"BATTLECREEK" IS ALREADY A $1MILLION+ HHSE MOVIE, AND THE REVENUES ARE JUST GETTING STARTED. SECOND LARGEST SHIPMENT EVER FOR HHSE.

http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html

HHSE - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture.

The SONY relationship includes the opportunity to place Hannover House represented titles into their network of direct distribution divisions in all major territories worldwide.

Status HHSE Audits, Form 10, Uplist To OTCQB

HHSE What's in Store for the first half of 2018?


a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

HHSE -- NO DILUTION in over 2.5 years!

1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

HHSE is a screaming buy!
Where we have been... Where we are now... and Where we are going at HHSE...

WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?

* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.

* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.

What else is worth noting for this long, holiday weekend? Here are a few observations:

1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.

3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.

The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.

A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.

There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

Where we have been... Where we are now... and Where we are going at HHSE...

WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?

* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.

* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.

What else is worth noting for this long, holiday weekend? Here are a few observations:

1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.

3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.

The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.

A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.

There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

HHSE Board of Directors approves Uplisting / Registration Costs

Dear HHSE Friends, Followers & Shareholders: At a special meeting of the Board of Directors of Hannover House, Inc., held on Thursday, October 19 at 11:00-am, the Board voted unanimously to immediately reinstate the prior filing activities to register the company's stock shares with the Securities and Exchange Commission (Form 10). The Board also authorized the following budgetary expenditures - to be funded from ongoing cash flows - to promptly complete this task:

HHSE

Steps and Budget for UPLISTING




Item
Description
Amount
1
Internal Data Entry
$ 4,000
2
Completion of New Library Valuation
$ 20,000
3
Outside CPA Review
$ 4,500
4
PCAOB Audit
$ 50,000
5
Legal Review & Drafting
$ 6,500
6
Registration S.E.C. Filings & XBRL
$ 3,250




FIRST TIME - UPLIST REGISTRATION COSTS
$ 88,250




Ongoing Quarterly Auditor's Review
$ 5,000

Ongoing Quarterly Attorney's Review
$ 2,000

Annual Review of Q4 & prior 3-Q's
$ 20,000

Annual Attorney review and drafting
$ 3,000




ANNUAL MAINTENANCE TOTALS
$ 44,000



The one-time costs for the registration / uplist are estimated at $88,250. The ongoing (annualized) maintenance costs are estimated at $44,000 (inclusive of the Quarterly Reviews by the PCAOB Auditing firm, and the annual year-end report and legal review).

Based on current cash flow and resources - and considering the anticipated benefits to the Company and its shareholders for HHSE as a fully registered equity - the Board has authorized the immediate implementation of this plan and the authorization of these expenditures.

The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows.
****
PRODUCT$-PRODUCT$-PRODUCT$. GETTING.GRACE-WHERE'S.THE.DRAGON-BLOODFEAST-DAISY.WINTERS-BATTLECREEK & OTHERS

GETTING GRACE - Hot on the heels of a major NYC Market festival SWEEP of all major awards, HHSE will be releasing this Faith-Based Comedy-Drama nationwide on February 10, 2018 - with an outreach campaign that includes mega-churches and a key-market BUS TOUR with star and director DANIEL ROEBUCK ("Matlock", "The Fugitive") to drive local market enthusiasm.

WHERE'S THE DRAGON - With the dissolution of the merger between HHSE and Crimson Forest, the company is finally cleared to revert back to the terms of the Dec. 2016 distribution agreement for this title. Accordingly, on February 3, 2018, this enchanting Animated Feature will be released to theatres in key markets, in advance of a May, 2018 Home Video and V.O.D. launch.

DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant) number of theatres!

CHOSEN - this impressive World War II thriller continues to get theatrical bookings in key USA markets, and now into CANADA (Toronto, Ottawa, Calgary and Vancouver)... watch for playdates in December and January.

BLOODFEAST - Now that the MPAA has approved our fourth edit for "R-Rating Status" - we can FINALLY get mainstream theatres to book this picture... watch for a roll-out beginning Nov. 17 into top markets (staggered over a 2-month period).


DAISY WINTERS - a much broader release (over 100 theatres) is set for December 1st for this awards-worthy drama featuring stunning performances from Brooke Shields and a breakout performance from young Sterling Jerins in the title role. The Media support has already begun, fueled by the Hannover House MEDIA DAY in NYC on Sept. 26, plus a special event premiere at the Regal Union Square (NYC) on Oct. 5. Already, Brooke has appeared on several national talk shows promoting DAISY WINTERS, including Bravo's WATCH WHAT HAPPENS LIVE and the highly rated TODAY SHOW on NBC. Much more to come, including major feature stories in People Magazine, USA Today, Closer, In-Touch, ACCESS HOLLYWOOD, EXTRA and E! TV.

BATTLECREEK - the acclaimed dramatic thriller from director ALISON EASTWOOD opens in two weeks (Nov. 3), in approx. 20 locations in key USA Markets. The film's primary star is BILL SKARSGARD, well-known from his current smash hit "IT" (he plays Pennywise, the scary clown), and his upcoming Stephen King TV series, "Castlerock." We have been fortunate to receive major media support for BATTLECREEK, including National TV show placements on: ACCESS HOLLYWOOD, EXTRA, E! and ENTERTAINMENT TONIGHT, and Alison Eastwood interview appearances on FOX AND FRIENDS, THE VIEW, TALK, GOOD DAY NY and HOME AND FAMILY. There will be an "Eastwood Family Screening Event" in Los Angeles on opening night (Nov. 3), which will be open to the public (and is expected to generate good attendance).

****
BOGUS DEFAULT JUDGMENTS EVAPORATED: PHOTOG($2.2M),TCA($400K),REDBULL($250K),AMITYVILLE($300K).

THESE BOGUS DEFAULTS WERE SUPPOSED TO BK THE COMPANY. LMAO.
****
VODWIZ UPDATE - As anticipated, we have closed a major studio venture that will provide tonnage of product to VODWIZ, including a large quantity of recent, theatrical hits. The totality of programming that will be available to consumers through VODWIZ appears to be on track to being second only to Amazon at this point. We see VODWIZ as a major portal for home entertainment digital streaming access, and potentially "the tail that wags the dog" so to speak. Additionally, we are about a week away from the anticipated finalization of a private funding structure to finance the costs associated with building the VODWIZ website (to Amazon Digital infrastructure standards), and all other pre-launch and initial consumer launch costs for this venture.

MORE VODWIZ - there's another MAJOR STUDIO ALERT in the works! Over the past three years of development, two Major Studios (each offering a small "test quantity" of titles for VODWIZ), were secured to support the initial launch of this streaming operation. Now, we are poised for a very major development of a third Major Studio with over 500 high-profile, ready-to-place titles available for the VODWIZ streaming platform. HHSE key managers (Fred Shefte and Eric Parkinson) are meeting at the studio in southern California on Friday to discuss the logistics of this venture, which is already documented through a participation term sheet.
****
DAISY WINTERS WILL EASILY MAKE $2.5M+ FROM POST-THEATRICAL REVENUE SOURCES SUCH AS DVDS, BLUE RAYS, TV AND VOD (NETFLIX, VODWIZ, ETC). AS EVERYONE KNOWS, A THEATRICAL RELEASE SIMPLY SATISFIES REQUIREMENTS AND GREATLY AMPLIFIES LIFETIME REVENUES OF A TITLE.


"BATTLECREEK" PROVED THAT POST-THEATRICAL PROCEEDS ARE WHAT MATTER. THEATRICAL RELEASE OF SMALL INDIE MOVIES ARE JUST PRE-REQUISITES FOR MUCH LARGER PROFITS FROM DVD, BLUE RAY, VOD AND TV REVENUES. JUST LOOK AT THE RATIO OF BATTLECREEK PROCEEDS FROM BOX OFFICE VS. $1M+ PROCEEDS FROM POST-THEATRICAL REVENUES.

BUT EVERYONE ALREADY KNEW THIS, SINCE IT WAS CLEARLY EXPLAINED IN THE BLOGS AND PROVEN IN THE MARKETPLACE MANY TIMES.


http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html

How major? Well - based on video preorders already received from Walmart, Target, Best Buy, K-Mart and Family Video - BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.

***
"BATTLECREEK" IS ALREADY A $1MILLION+ HHSE MOVIE, AND THE REVENUES ARE JUST GETTING STARTED. SECOND LARGEST SHIPMENT EVER FOR HHSE.

http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html

With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture.

The SONY relationship includes the opportunity to place Hannover House represented titles into their network of direct distribution divisions in all major territories worldwide.

Status HHSE Audits, Form 10, Uplist To OTCQB

What's in Store for the first half of 2018?


a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

HHSE -- NO DILUTION in over 2.5 years!

1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

HHSE is a screaming buy!
Where we have been... Where we are now... and Where we are going at HHSE...

WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?

* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.

* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.

What else is worth noting for this long, holiday weekend? Here are a few observations:

1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.

3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.

The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.

A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.

There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

Where we have been... Where we are now... and Where we are going at HHSE...

WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?

* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.

* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.

What else is worth noting for this long, holiday weekend? Here are a few observations:

1). Hannover House has Not Issued any Shares in 2.5-years. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.

3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.

The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.

A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.

There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

IRS ACKNOWLEDGES LEVY ERROR -

HHSE management is pleased to report that a levy issued by the IRS for "estimated payroll taxes" has been corrected and relieved after providing required documentation for the payroll reporting periods previously in question. We have been told that the IRS levy will be lifted (and customers notified) within the next 21 days, and the future reporting of payroll taxes (through our third-party payroll service) will correctly identify the Employer I.D. Numbers that sparked the arbitrary / estimated assessment in the first place.

HHSE is a screaming buy!
Where we have been... Where we are now... and Where we are going at HHSE...

WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?

* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.

* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.

What else is worth noting for this long, holiday weekend? Here are a few observations:

1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.

3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.

The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.

A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.

There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

The GOOD NEWS is that the markets are FORWARD LOOKING: http://tinyurl.com/y9unalzo

And HHSE appears to be attracting HIGHER QUALITY talent in Clint Eastwoods daughter: Alison Eastwood directing "Battlecreek" (& the "IT" star), with Brook Shields (who most recently has been appearing everywhere), along with "Game of Thrones" star ("Ramsey Bolton" aka Iwan Rheon) in "Daisy Winters" & other recent HHSE theatrical releases & NEW franchise titles forthcoming...
http://tinyurl.com/y9dvn9oq


HHSE has had success in the past with retail releases into; Walmart, Redbox, Netflix, Target, & others such that all this RECENT ACTIVITY bodes well for them going forward.


Mrkets are FORWARD LOOKING... & in the OTC HUGE GAINS may be had for stocks like this: Especially ones that DO NOT DILUTE.

As HHSE has NOT DILUTED in OVER 2.5 YEARS now...


Which means there are NO OVERHEAD shares to be sold down into any NEW buyers & holders. With all the forward-looking catalysts like CANNES Film Festival, NEW titles, titles heading to retail NEXT QUARTER & the like I think HHSE may be worth a BUY rating at these prices.

Apparently there is some AGREEMENT in this regard since the CHARTS & TECHNICALS are moving in FAVOR of UPSIDE VALUE & upside gains for those buying HHSE at these levels.

FORM10-AUDIT-UPLIST: A PROCESS, NOT A ONE-DAY EVENT,

THERE IS A 60-DAY SEC REVIEW PERIOD (POSSIBLY FASTER) BEFORE HHSE UPLISTS TO OTCQB. THEREFORE, IT'S ACCURATE TO SAY THE PROCESS IS "STARTING" IN JANUARY. BUT, EVERYONE ALREADY KNEW THAT. LOL

AUDITED 2016 FINANCIALS
UPDATED LIBRARY VALUATION
AUDITED 2017 FINANCIALS
AUDIT LETTER - FORM 10
SEC REVIEW (60 DAYS MAX)
UPLIST TO OTCQB


SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED
Stockholders are long and strong! Go Eric! Go HHSE!

HHSE Board of Directors approves Uplisting / Registration Costs

Dear HHSE Friends, Followers & Shareholders: At a special meeting of the Board of Directors of Hannover House, Inc., held on Thursday, October 19 at 11:00-am, the Board voted unanimously to immediately reinstate the prior filing activities to register the company's stock shares with the Securities and Exchange Commission (Form 10). The Board also authorized the following budgetary expenditures - to be funded from ongoing cash flows - to promptly complete this task:

HHSE

Steps and Budget for UPLISTING




Item
Description
Amount
1
Internal Data Entry
$ 4,000
2
Completion of New Library Valuation
$ 20,000
3
Outside CPA Review
$ 4,500
4
PCAOB Audit
$ 50,000
5
Legal Review & Drafting
$ 6,500
6
Registration S.E.C. Filings & XBRL
$ 3,250




FIRST TIME - UPLIST REGISTRATION COSTS
$ 88,250




Ongoing Quarterly Auditor's Review
$ 5,000

Ongoing Quarterly Attorney's Review
$ 2,000

Annual Review of Q4 & prior 3-Q's
$ 20,000

Annual Attorney review and drafting
$ 3,000




ANNUAL MAINTENANCE TOTALS
$ 44,000



The one-time costs for the registration / uplist are estimated at $88,250. The ongoing (annualized) maintenance costs are estimated at $44,000 (inclusive of the Quarterly Reviews by the PCAOB Auditing firm, and the annual year-end report and legal review).

Based on current cash flow and resources - and considering the anticipated benefits to the Company and its shareholders for HHSE as a fully registered equity - the Board has authorized the immediate implementation of this plan and the authorization of these expenditures.

The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows.
****
PRODUCT$-PRODUCT$-PRODUCT$. GETTING.GRACE-WHERE'S.THE.DRAGON-BLOODFEAST-DAISY.WINTERS-BATTLECREEK & OTHERS

GETTING GRACE - Hot on the heels of a major NYC Market festival SWEEP of all major awards, HHSE will be releasing this Faith-Based Comedy-Drama nationwide on February 10, 2018 - with an outreach campaign that includes mega-churches and a key-market BUS TOUR with star and director DANIEL ROEBUCK ("Matlock", "The Fugitive") to drive local market enthusiasm.

WHERE'S THE DRAGON - With the dissolution of the merger between HHSE and Crimson Forest, the company is finally cleared to revert back to the terms of the Dec. 2016 distribution agreement for this title. Accordingly, on February 3, 2018, this enchanting Animated Feature will be released to theatres in key markets, in advance of a May, 2018 Home Video and V.O.D. launch.

DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant) number of theatres!

CHOSEN - this impressive World War II thriller continues to get theatrical bookings in key USA markets, and now into CANADA (Toronto, Ottawa, Calgary and Vancouver)... watch for playdates in December and January.

BLOODFEAST - Now that the MPAA has approved our fourth edit for "R-Rating Status" - we can FINALLY get mainstream theatres to book this picture... watch for a roll-out beginning Nov. 17 into top markets (staggered over a 2-month period).


DAISY WINTERS - a much broader release (over 100 theatres) is set for December 1st for this awards-worthy drama featuring stunning performances from Brooke Shields and a breakout performance from young Sterling Jerins in the title role. The Media support has already begun, fueled by the Hannover House MEDIA DAY in NYC on Sept. 26, plus a special event premiere at the Regal Union Square (NYC) on Oct. 5. Already, Brooke has appeared on several national talk shows promoting DAISY WINTERS, including Bravo's WATCH WHAT HAPPENS LIVE and the highly rated TODAY SHOW on NBC. Much more to come, including major feature stories in People Magazine, USA Today, Closer, In-Touch, ACCESS HOLLYWOOD, EXTRA and E! TV.

BATTLECREEK - the acclaimed dramatic thriller from director ALISON EASTWOOD opens in two weeks (Nov. 3), in approx. 20 locations in key USA Markets. The film's primary star is BILL SKARSGARD, well-known from his current smash hit "IT" (he plays Pennywise, the scary clown), and his upcoming Stephen King TV series, "Castlerock." We have been fortunate to receive major media support for BATTLECREEK, including National TV show placements on: ACCESS HOLLYWOOD, EXTRA, E! and ENTERTAINMENT TONIGHT, and Alison Eastwood interview appearances on FOX AND FRIENDS, THE VIEW, TALK, GOOD DAY NY and HOME AND FAMILY. There will be an "Eastwood Family Screening Event" in Los Angeles on opening night (Nov. 3), which will be open to the public (and is expected to generate good attendance).

****
BOGUS DEFAULT JUDGMENTS EVAPORATED: PHOTOG($2.2M),TCA($400K),REDBULL($250K),AMITYVILLE($300K).

THESE BOGUS DEFAULTS WERE SUPPOSED TO BK THE COMPANY. LMAO.
****
VODWIZ UPDATE - As anticipated, we have closed a major studio venture that will provide tonnage of product to VODWIZ, including a large quantity of recent, theatrical hits. The totality of programming that will be available to consumers through VODWIZ appears to be on track to being second only to Amazon at this point. We see VODWIZ as a major portal for home entertainment digital streaming access, and potentially "the tail that wags the dog" so to speak. Additionally, we are about a week away from the anticipated finalization of a private funding structure to finance the costs associated with building the VODWIZ website (to Amazon Digital infrastructure standards), and all other pre-launch and initial consumer launch costs for this venture.

MORE VODWIZ - there's another MAJOR STUDIO ALERT in the works! Over the past three years of development, two Major Studios (each offering a small "test quantity" of titles for VODWIZ), were secured to support the initial launch of this streaming operation. Now, we are poised for a very major development of a third Major Studio with over 500 high-profile, ready-to-place titles available for the VODWIZ streaming platform. HHSE key managers (Fred Shefte and Eric Parkinson) are meeting at the studio in southern California on Friday to discuss the logistics of this venture, which is already documented through a participation term sheet.
****
DAISY WINTERS WILL EASILY MAKE $2.5M+ FROM POST-THEATRICAL REVENUE SOURCES SUCH AS DVDS, BLUE RAYS, TV AND VOD (NETFLIX, VODWIZ, ETC). AS EVERYONE KNOWS, A THEATRICAL RELEASE SIMPLY SATISFIES REQUIREMENTS AND GREATLY AMPLIFIES LIFETIME REVENUES OF A TITLE.


"BATTLECREEK" PROVED THAT POST-THEATRICAL PROCEEDS ARE WHAT MATTER. THEATRICAL RELEASE OF SMALL INDIE MOVIES ARE JUST PRE-REQUISITES FOR MUCH LARGER PROFITS FROM DVD, BLUE RAY, VOD AND TV REVENUES. JUST LOOK AT THE RATIO OF BATTLECREEK PROCEEDS FROM BOX OFFICE VS. $1M+ PROCEEDS FROM POST-THEATRICAL REVENUES.

BUT EVERYONE ALREADY KNEW THIS, SINCE IT WAS CLEARLY EXPLAINED IN THE BLOGS AND PROVEN IN THE MARKETPLACE MANY TIMES.


http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html

How major? Well - based on video preorders already received from Walmart, Target, Best Buy, K-Mart and Family Video - BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.

***
"BATTLECREEK" IS ALREADY A $1MILLION+ HHSE MOVIE, AND THE REVENUES ARE JUST GETTING STARTED. SECOND LARGEST SHIPMENT EVER FOR HHSE.

http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html

With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture.

The SONY relationship includes the opportunity to place Hannover House represented titles into their network of direct distribution divisions in all major territories worldwide.

Status HHSE Audits, Form 10, Uplist To OTCQB

What's in Store for the first half of 2018?


a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

HHSE -- NO DILUTION in over 2.5 years!

1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

HHSE OTCQB UPLIST In 2018: With No Dilution



* AUDITED 2016 FINANCIALS

* UPDATED LIBRARY VALUATION

* AUDITED 2017 FINANCIALS

* AUDIT LETTER - FORM 10

* SEC REVIEW (60 DAYS MAX)

* UPLIST TO OTCQB

Stockholders are long and strong! Go Eric! Go HHSE!

FORM10-AUDIT-UPLIST: A PROCESS, NOT A ONE-DAY EVENT, BUT EVERYONE ALREADY KNOWS THAT. THERE IS A 60-DAY SEC REVIEW PERIOD (POSSIBLY FASTER) BEFORE HHSE UPLISTS TO OTCQB. THEREFORE, IT'S ACCURATE TO SAY THE PROCESS IS "STARTING" IN JANUARY. BUT, EVERYONE ALREADY KNEW THAT. LOL

AUDITED 2016 FINANCIALS
UPDATED LIBRARY VALUATION
AUDITED 2017 FINANCIALS
AUDIT LETTER - FORM 10
SEC REVIEW (60 DAYS MAX)
UPLIST TO OTCQB


SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED
Stockholders are long and strong! Go Eric! Go HHSE!

HHSE Board of Directors approves Uplisting / Registration Costs

Dear HHSE Friends, Followers & Shareholders: At a special meeting of the Board of Directors of Hannover House, Inc., held on Thursday, October 19 at 11:00-am, the Board voted unanimously to immediately reinstate the prior filing activities to register the company's stock shares with the Securities and Exchange Commission (Form 10). The Board also authorized the following budgetary expenditures - to be funded from ongoing cash flows - to promptly complete this task:

HHSE

Steps and Budget for UPLISTING




Item
Description
Amount
1
Internal Data Entry
$ 4,000
2
Completion of New Library Valuation
$ 20,000
3
Outside CPA Review
$ 4,500
4
PCAOB Audit
$ 50,000
5
Legal Review & Drafting
$ 6,500
6
Registration S.E.C. Filings & XBRL
$ 3,250




FIRST TIME - UPLIST REGISTRATION COSTS
$ 88,250




Ongoing Quarterly Auditor's Review
$ 5,000

Ongoing Quarterly Attorney's Review
$ 2,000

Annual Review of Q4 & prior 3-Q's
$ 20,000

Annual Attorney review and drafting
$ 3,000




ANNUAL MAINTENANCE TOTALS
$ 44,000



The one-time costs for the registration / uplist are estimated at $88,250. The ongoing (annualized) maintenance costs are estimated at $44,000 (inclusive of the Quarterly Reviews by the PCAOB Auditing firm, and the annual year-end report and legal review).

Based on current cash flow and resources - and considering the anticipated benefits to the Company and its shareholders for HHSE as a fully registered equity - the Board has authorized the immediate implementation of this plan and the authorization of these expenditures.

The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows.
****
PRODUCT$-PRODUCT$-PRODUCT$. GETTING.GRACE-WHERE'S.THE.DRAGON-BLOODFEAST-DAISY.WINTERS-BATTLECREEK & OTHERS

GETTING GRACE - Hot on the heels of a major NYC Market festival SWEEP of all major awards, HHSE will be releasing this Faith-Based Comedy-Drama nationwide on February 10, 2018 - with an outreach campaign that includes mega-churches and a key-market BUS TOUR with star and director DANIEL ROEBUCK ("Matlock", "The Fugitive") to drive local market enthusiasm.

WHERE'S THE DRAGON - With the dissolution of the merger between HHSE and Crimson Forest, the company is finally cleared to revert back to the terms of the Dec. 2016 distribution agreement for this title. Accordingly, on February 3, 2018, this enchanting Animated Feature will be released to theatres in key markets, in advance of a May, 2018 Home Video and V.O.D. launch.

DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant) number of theatres!

CHOSEN - this impressive World War II thriller continues to get theatrical bookings in key USA markets, and now into CANADA (Toronto, Ottawa, Calgary and Vancouver)... watch for playdates in December and January.

BLOODFEAST - Now that the MPAA has approved our fourth edit for "R-Rating Status" - we can FINALLY get mainstream theatres to book this picture... watch for a roll-out beginning Nov. 17 into top markets (staggered over a 2-month period).


DAISY WINTERS - a much broader release (over 100 theatres) is set for December 1st for this awards-worthy drama featuring stunning performances from Brooke Shields and a breakout performance from young Sterling Jerins in the title role. The Media support has already begun, fueled by the Hannover House MEDIA DAY in NYC on Sept. 26, plus a special event premiere at the Regal Union Square (NYC) on Oct. 5. Already, Brooke has appeared on several national talk shows promoting DAISY WINTERS, including Bravo's WATCH WHAT HAPPENS LIVE and the highly rated TODAY SHOW on NBC. Much more to come, including major feature stories in People Magazine, USA Today, Closer, In-Touch, ACCESS HOLLYWOOD, EXTRA and E! TV.

BATTLECREEK - the acclaimed dramatic thriller from director ALISON EASTWOOD opens in two weeks (Nov. 3), in approx. 20 locations in key USA Markets. The film's primary star is BILL SKARSGARD, well-known from his current smash hit "IT" (he plays Pennywise, the scary clown), and his upcoming Stephen King TV series, "Castlerock." We have been fortunate to receive major media support for BATTLECREEK, including National TV show placements on: ACCESS HOLLYWOOD, EXTRA, E! and ENTERTAINMENT TONIGHT, and Alison Eastwood interview appearances on FOX AND FRIENDS, THE VIEW, TALK, GOOD DAY NY and HOME AND FAMILY. There will be an "Eastwood Family Screening Event" in Los Angeles on opening night (Nov. 3), which will be open to the public (and is expected to generate good attendance).

****
BOGUS DEFAULT JUDGMENTS EVAPORATED: PHOTOG($2.2M),TCA($400K),REDBULL($250K),AMITYVILLE($300K).

THESE BOGUS DEFAULTS WERE SUPPOSED TO BK THE COMPANY. LMAO.
****
VODWIZ UPDATE - As anticipated, we have closed a major studio venture that will provide tonnage of product to VODWIZ, including a large quantity of recent, theatrical hits. The totality of programming that will be available to consumers through VODWIZ appears to be on track to being second only to Amazon at this point. We see VODWIZ as a major portal for home entertainment digital streaming access, and potentially "the tail that wags the dog" so to speak. Additionally, we are about a week away from the anticipated finalization of a private funding structure to finance the costs associated with building the VODWIZ website (to Amazon Digital infrastructure standards), and all other pre-launch and initial consumer launch costs for this venture.

MORE VODWIZ - there's another MAJOR STUDIO ALERT in the works! Over the past three years of development, two Major Studios (each offering a small "test quantity" of titles for VODWIZ), were secured to support the initial launch of this streaming operation. Now, we are poised for a very major development of a third Major Studio with over 500 high-profile, ready-to-place titles available for the VODWIZ streaming platform. HHSE key managers (Fred Shefte and Eric Parkinson) are meeting at the studio in southern California on Friday to discuss the logistics of this venture, which is already documented through a participation term sheet.
****
DAISY WINTERS WILL EASILY MAKE $2.5M+ FROM POST-THEATRICAL REVENUE SOURCES SUCH AS DVDS, BLUE RAYS, TV AND VOD (NETFLIX, VODWIZ, ETC). AS EVERYONE KNOWS, A THEATRICAL RELEASE SIMPLY SATISFIES REQUIREMENTS AND GREATLY AMPLIFIES LIFETIME REVENUES OF A TITLE.


"BATTLECREEK" PROVED THAT POST-THEATRICAL PROCEEDS ARE WHAT MATTER. THEATRICAL RELEASE OF SMALL INDIE MOVIES ARE JUST PRE-REQUISITES FOR MUCH LARGER PROFITS FROM DVD, BLUE RAY, VOD AND TV REVENUES. JUST LOOK AT THE RATIO OF BATTLECREEK PROCEEDS FROM BOX OFFICE VS. $1M+ PROCEEDS FROM POST-THEATRICAL REVENUES.

BUT EVERYONE ALREADY KNEW THIS, SINCE IT WAS CLEARLY EXPLAINED IN THE BLOGS AND PROVEN IN THE MARKETPLACE MANY TIMES.


http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html

How major? Well - based on video preorders already received from Walmart, Target, Best Buy, K-Mart and Family Video - BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.

***
"BATTLECREEK" IS ALREADY A $1MILLION+ HHSE MOVIE, AND THE REVENUES ARE JUST GETTING STARTED. SECOND LARGEST SHIPMENT EVER FOR HHSE.

http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html

With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture.

The SONY relationship includes the opportunity to place Hannover House represented titles into their network of direct distribution divisions in all major territories worldwide.

Status HHSE Audits, Form 10, Uplist To OTCQB

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

HHSE -- NO DILUTION in over 2.5 years!

1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

HHSE -- NO DILUTION in over 2.5 years!

1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

(1)During the Merger Process with Crimson Forest, Company purposely delayed the release of five (5) new release Home Video and V.O.D. titles, which will be released later in 2017. Company projects that the gross revenue value of the delayed titles is approx. $750,000.


BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.

Successfully releasing independent films is a strategy and process involving multiple revenues streams and steps to achieve the best, bottom-line result. We are happy with the launch of BATTLECREEK, and know that our year-end financials will demonstrate the validity of this strategy.


Although the Crimson merger will not occur, the uplist will proceed, and the maturation of the company to "the next level" is already well underway. We are now partnered with a Major Studio for distribution; we're Executive Producers / Worldwide Distributors on two CURRENT productions; we have two major titles in theatrical release (Nov. 3 and Dec. 1) and four "genre'" titles for more limited release in the next few months (see below); we have more than doubled the title library for VODWIZ, and partnered with the world's leading digital services operator (Amazon); we have new release DVD and BluRays in the pipeline for February, March, April and May (collectively generating over $4-million in gross shipments), and we are in final documentation of major financing agreements to cover the epic productions of MOTHER GOOSE and MELTDOWN (each of which is transformative in what they will do for HHSE's profile and revenues).


Then there is new Sony Distribution Pact set to kick in 2018

Some where along this path:
* Form 10 (Jan/Feb)
* HHSE OTCQB (after Form 10, SEC 60 day Review)

HHSE MATURATION TO "THE NEXT LEVEL" ALREADY WELL UNDERWAY


1.) HHSE UPLIST to OTCQB (March/April)

2.) HHSE Distribution Partner with Major Studio.

3.) HHSE Executve Producers / Worldwide Distributors on Two CURRENT Productions.

4.) Two Major Titles In Theatrical Releases.
- a.) "BATTLECREEK"
- b.) "DAISY WINTERS"

5.) Four Genre Titles In Limited Theatrical Releases Soon.
- a.) "BLOODFEAST"
- b.) "CHOSEN"
- c.) "DEATH HOUSE"
- d.) "WHERE'S THE DRAGON?"

6.) VODwiz - Online Independent Films Streaming Portal
- a.) Doubled Titles Library (Second only to Amazon at this point).
- b.) Partnered with Amazon the World's Leading Digital Services Operator.

7.) DVD & BluRay New Releases Pipeline (12 Titles, $4,000,000+ Gross Shipments).

8.) Two Major Financing Agreements of Epic Productions (Transform HHSE Profile & Revenues).
- a.) "MOTHER GOOSE"
- b.) "MELTDOWN"



*** The future is bright and the future is RIGHT NOW ***

HHSE is a screaming buy!

Where we have been... Where we are now... and Where we are going at HHSE... (Readers Digest version)
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?

* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.

* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.

What else is worth noting for this long, holiday weekend? Here are a few observations:

1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.

3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.

The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.

A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.

There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

The GOOD NEWS is that the markets are FORWARD LOOKING: http://tinyurl.com/y9unalzo

And HHSE appears to be attracting HIGHER QUALITY talent in Clint Eastwoods daughter: Alison Eastwood directing "Battlecreek" (& the "IT" star), with Brook Shields (who most recently has been appearing everywhere), along with "Game of Thrones" star ("Ramsey Bolton" aka Iwan Rheon) in "Daisy Winters" & other recent HHSE theatrical releases & NEW franchise titles forthcoming...
http://tinyurl.com/y9dvn9oq


HHSE has had success in the past with retail releases into; Walmart, Redbox, Netflix, Target, & others such that all this RECENT ACTIVITY bodes well for them going forward.


Mrkets are FORWARD LOOKING... & in the OTC HUGE GAINS may be had for stocks like this: Especially ones that DO NOT DILUTE.

As HHSE has NOT DILUTED in OVER 2.5 YEARS now...


Which means there are NO OVERHEAD shares to be sold down into any NEW buyers & holders. With all the forward-looking catalysts like CANNES Film Festival, NEW titles, titles heading to retail NEXT QUARTER & the like I think HHSE may be worth a BUY rating at these prices.

Apparently there is some AGREEMENT in this regard since the CHARTS & TECHNICALS are moving in FAVOR of UPSIDE VALUE & upside gains for those buying HHSE at these levels.

Where we have been... Where we are now... and Where we are going at HHSE...

Greetings HHSE Friends & Followers:

As we reflect back on 2017, HHSE Management is taking a few days to look at our past, present and future activities to help guide sage decisions. 2017 has been a momentous year for the company - due in large part to the attempted (but terminated) merger with Crimson Forest, and the subsequent re-focus of the company's primary activities and revenue streams.

Looking much further back - five, six, seven years and more - and looking forward in time for an equal time-frame, we can see trends and opportunities for HHSE and our shareholders.

First of all, we'd like to point out that Hannover House is unlike most any other "OTC Pinksheet" listed company. We have been operating continuously since 1993 (24-years) and have been reporting to the OTC Markets since Dec. 2009 (8-years). Statistically, most OTC listed equities are flashes-in-the-pan time wise... lots of Stock Hype / I.R. Promotions, insider share dumps, and quick closures. That's definitely not HHSE.

As a result of this general trend for Pinksheet companies, a whole sub-industry of stock manipulators has developed that can impact OTC-Pinksheet listed companies (for the entirety of OTC markets in general, not specifically limited to Hannover House). Like a gang of drunken hobos in public park - mumbling to each other with insane prognostications - the stock hobos are only effective against low-information shareholders gullible enough to actually read the chat-board postings of manipulative and fact-free ramblings.

Fortunately, every false statement made by the stock hobos or those manipulators attempting to "box" or otherwise control the HHSE stock price, can be easily countered with demonstrable facts.

So, let's take a few minutes to take a high-altitude look at the Company and where we are going.

WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?

* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.

* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.

What else is worth noting for this long, holiday weekend? Here are a few observations:

1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.

3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.

4). What's in Store for the first half of 2018?

a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initial theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).

b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.

5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.

The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.

A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.

There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occurring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!

http://hannoverhousemovies.blogspot.com/2017/...w-and.html

HHSE With big distribution partnerships with Sony Pictures and Cinedigm!

Quote:
We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...

Quote:
The SONY relationship includes the opportunity to place Hannover House represented titles into their network of direct distribution divisions in all major territories worldwide.

During the Merger Process with Crimson Forest, Company purposely delayed the release of five (5) new release Home Video and V.O.D. titles, which will be released later in 2017. Company projects that the gross revenue value of the delayed titles is approx. $750,000.

SONY+CINEDIGM+HHSE

HHSE -- NO DILUTION in over 2.5 years!


1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.

Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).

The GOOD NEWS is that the markets are FORWARD LOOKING: http://tinyurl.com/y9unalzo

And HHSE appears to be attracting HIGHER QUALITY talent in Clint Eastwoods daughter: Alison Eastwood directing "Battlecreek" (& the "IT" star), with Brook Shields (who most recently has been appearing everywhere), along with "Game of Thrones" star ("Ramsey Bolton" aka Iwan Rheon) in "Daisy Winters" & other recent HHSE theatrical releases & NEW franchise titles forthcoming...
http://tinyurl.com/y9dvn9oq


HHSE has had success in the past with retail releases into; Walmart, Redbox, Netflix, Target, & others such that all this RECENT ACTIVITY bodes well for them going forward.


Mrkets are FORWARD LOOKING... & in the OTC HUGE GAINS may be had for stocks like this: Especially ones that DO NOT DILUTE.

As HHSE has NOT DILUTED in OVER 2.5 YEARS now...


Which means there are NO OVERHEAD shares to be sold down into any NEW buyers & holders. With all the forward-looking catalysts like CANNES Film Festival, NEW titles, titles heading to retail NEXT QUARTER & the like I think HHSE may be worth a BUY rating at these prices.

Apparently there is some AGREEMENT in this regard since the CHARTS & TECHNICALS are moving in FAVOR of UPSIDE VALUE & upside gains for those buying HHSE at these levels.